Keywords: Valeant, Brazil, M&A, Branded generics, OTC medicines, Manufacturing plant
Valeant buys Brazilian branded generics/OTC firm for $28 million and pays further $28 million for manufacturing facility
Article | 22 March 2010
California, USA-based Valeant Pharmaceuticals International says it has signed a binding agreement to acquire a private, branded generics and over-the-counter ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
